OXURION (EBR:OXUR) | Finanzwire

Basculer en Français

10621	Companies
225706	Keywords
154266	Articles
119431	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 06/08/2026 at 21:00, 15 days 8 hours ago

Oxurion launches a software-driven growth strategy with Exagis
Oxurion NV announces the software-driven growth strategy launch centered on Exagis, its proprietary clinical research platform. The platform evolves into a broad CDMS commercially serving clinical development market

Oxurion NV Exagis Clinical Research Platform Software-driven Growth Strategy CDMS
BRIEF

published on 06/03/2026 at 18:05, 20 days 11 hours ago

Oxurion Announces the Results of its Annual General Meeting

Pharmaceutical Investments General Assembly Results Oxurion
BRIEF

published on 06/03/2026 at 18:05, 20 days 11 hours ago

Oxurion Approves Agenda at Annual Shareholders' Meeting

Forward-looking Statements Shareholders' Meeting Oxurion NV Leuven Agenda Approval
PRESS RELEASE

published on 06/03/2026 at 18:00, 20 days 11 hours ago

Oxurion Announces Results on the Annual Shareholders' Meeting of 1 June 2026
Oxurion NV (Euronext Brussels: OXUR) successfully held its annual shareholders' meeting in Leuven, with all agenda items approved. Find more about the biopharmaceutical company at oxurion.com

Biopharmaceutical Euronext Brussels Annual Shareholders' Meeting Oxurion NV Leuven
BRIEF

published on 06/02/2026 at 18:05, 21 days 11 hours ago

Oxurion Expands Services to Meet Growing Demand in GLP-1 Clinical Research

Clinical Research Oxurion Peptide Therapeutics GLP-1 Market Biometrics Services
BRIEF

published on 06/02/2026 at 18:05, 21 days 11 hours ago

Oxurion expands its clinical research offering targeting GLP-1 and peptides

Clinical Research GLP-1 Oxurion Peptides Biometrics
PRESS RELEASE

published on 06/02/2026 at 18:00, 21 days 11 hours ago

Oxurion expands its capabilities to address the growing demand for GLP-1 and peptide clinical research services
Oxurion NV launches specialized service offering focused on GLP-1 therapies, peptide therapeutics, and biosimilar development. The company expands clinical research platform to meet growing market demands

Clinical Research GLP-1 Therapies Oxurion NV Peptide Therapeutics Biosimilar Development
BRIEF

published on 06/02/2026 at 08:05, 21 days 21 hours ago

Oxurion cancels its project in France to focus on an international target

Acquisition Clinical Development International Biopharmaceutical Oxurion
PRESS RELEASE

published on 06/02/2026 at 08:00, 21 days 21 hours ago

Oxurion - Termination of discussions for the French CRO project (LOI dated 13/10/25) and prioritization of the international target (LOI dated 19/03/26)
Oxurion NV terminates discussions on acquiring majority stake in French CRO and focuses on international CRO acquisition. Company details efforts to build integrated clinical research platform

Acquisition Clinical Research Pharmaceutical CRO Oxurion NV
BRIEF

published on 05/29/2026 at 18:05, 25 days 11 hours ago

Oxurion Reports Transparency Notifications from Atlas Special Opportunities II LLC

Shares Transparency Belgium Atlas Special Opportunities Oxurion

Accesswire

Published on 06/24/2026 at 03:15, 2 hours 26 minutes ago

Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 5 hours 41 minutes ago

Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 5 hours 56 minutes ago

Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 6 hours 21 minutes ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 6 hours 26 minutes ago

EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects

View all ACCESSWIRE

EQS Group

Published on 06/24/2026 at 04:00, 1 hour 41 minutes ago

Shipping edges closer to onboard carbon mineralisation as IMO endorses Shanghai Qiyao Technology Group Co., Ltd. proposals
Published on 06/24/2026 at 02:05, 3 hours 36 minutes ago

FRONTERA AND KUPARI ANNOUNCE COMMENCEMENT OF STRATEGIC SALE PROCESS FOR THE JOINTLY OWNED PIEDRAS VERDES COPPER MINE COMPLEX IN SONORA, MEXICO
Published on 06/23/2026 at 22:20, 7 hours 21 minutes ago

Saudi Properties Portal to Accept Applications for Foreign Real Estate Ownership
Published on 06/23/2026 at 20:15, 9 hours 26 minutes ago

EQS-Adhoc: OHB SE resolves on the issue of 1,605,388 new shares representing the first tranche of the up to 8.86% capital increase with subscription rights
Published on 06/23/2026 at 18:59, 10 hours 42 minutes ago

Holding(s) in Company

Les Echos

Published on 06/23/2026 at 19:47, 9 hours 53 minutes ago

GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 10 hours 31 minutes ago

GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 16:47, 12 hours 54 minutes ago

Statement of transactions in own shares from June 15, 2026 to June 19, 2026
Published on 06/23/2026 at 15:44, 13 hours 57 minutes ago

Guillemot Corporation S.A. | Weekly report share buyback from June 15 to June 19 2026
Published on 06/23/2026 at 14:00, 15 hours 41 minutes ago

Neoen awarded long-term contract for new 200 MW / 8-hour battery in Ontario, Canada

View all LES ECHOS COMFI WIRE